Xenon Pharmaceuticals Inc (XENE):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Xenon Pharmaceuticals Inc (XENE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7556
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Xenon Pharmaceuticals Inc (Xenon), formerly Xenon Genetics Inc, is a biopharmaceutical company that discovers and develops therapeutics for patients suffering with neurological disorders. The company’s pipeline products include XEN1101, XEN901, XEN007 and GDC-0310. It discovers various validated drug targets through the study of rare human diseases with extreme traits, including channelopathies and diseases caused by mutations in ion channels. Xenon’s target treatment areas include lipoprotein lipase deficiency, cardiovascular diseases, dermatology, pain and dravet syndrome. The company partners with pharmaceutical companies to access development and commercial resources, and non-dilutive funding to validate the advancement of diverse pipeline. Xenon is headquartered in Burnaby, British Columbia, Canada.

Xenon Pharmaceuticals Inc (XENE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Xenon Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Xenon Acquires Milestones and Royalties Related to XEN1101 Program from Valeant Pharma 12
Xenon Pharmaceuticals Acquires Development and Commercialization Rights for XEN1101 from 1st Order 13
Partnerships 14
Medpace Enters into Amendment Agreement with Xenon Pharma 14
Xenon Pharma Extends Agreement with Genentech 15
Licensing Agreements 16
Xenon Pharma Enters into Licensing Agreement with Pharma CMO 16
Xenon Pharma Enters into Licensing Agreement with Pharmaceutical Company 17
Xenon Pharma Exercises Option For Licensing Agreement With Isis Pharma For Antisense Drug XEN701 18
Equity Offering 20
Xenon Pharma Raises USD63 Million in Public Offering of Shares 20
Xenon Pharma to Raise up to USD30 Million in Public Offering of Shares 22
Xenon Pharma Completes Public Offering of Shares for USD34.5 Million 23
Xenon Pharma Raises USD41.4 Million in IPO of Shares 25
Xenon Pharmaceuticals Inc – Key Competitors 27
Xenon Pharmaceuticals Inc – Key Employees 28
Xenon Pharmaceuticals Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Aug 07, 2018: Xenon Pharmaceuticals reports second quarter 2018 financial results and provides corporate update 30
May 08, 2018: Xenon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update 33
Mar 07, 2018: Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update 35
Nov 07, 2017: Xenon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 38
Aug 03, 2017: Xenon Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update 40
May 09, 2017: Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 42
Mar 08, 2017: Xenon Pharmaceuticals Reports 2016 Financial Results and Provides Corporate Update 44
Corporate Communications 46
Mar 13, 2018: Dr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical Officer 46
Clinical Trials 47
Sep 06, 2018: Xenon expands ion channel neurology pipeline with addition of XEN496, a “Phase 3 Ready” potassium channel modulator for the treatment of epilepsy 47
Oct 17, 2017: Xenon Pharmaceuticals Announces Initiation of XEN1101 Phase 1 Clinical Trial 49
Jun 27, 2017: Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint 50
Jun 27, 2017: Xenon Pharmaceuticals to Host Conference Call and Webcast Today at 9:00 a.m. Eastern Time to Discuss Topline Results from TV-45070 Phase 2b Clinical Trial in PHN 51
Other Significant Developments 52
Jan 08, 2018: Xenon Pharmaceuticals Outlines Key Milestones for 2018 52
Jan 08, 2017: Xenon Pharmaceuticals Outlines Key Milestones for 2017 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Xenon Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Xenon Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Xenon Acquires Milestones and Royalties Related to XEN1101 Program from Valeant Pharma 12
Xenon Pharmaceuticals Acquires Development and Commercialization Rights for XEN1101 from 1st Order 13
Medpace Enters into Amendment Agreement with Xenon Pharma 14
Xenon Pharma Extends Agreement with Genentech 15
Xenon Pharma Enters into Licensing Agreement with Pharma CMO 16
Xenon Pharma Enters into Licensing Agreement with Pharmaceutical Company 17
Xenon Pharma Exercises Option For Licensing Agreement With Isis Pharma For Antisense Drug XEN701 18
Xenon Pharma Raises USD63 Million in Public Offering of Shares 20
Xenon Pharma to Raise up to USD30 Million in Public Offering of Shares 22
Xenon Pharma Completes Public Offering of Shares for USD34.5 Million 23
Xenon Pharma Raises USD41.4 Million in IPO of Shares 25
Xenon Pharmaceuticals Inc, Key Competitors 27
Xenon Pharmaceuticals Inc, Key Employees 28
Xenon Pharmaceuticals Inc, Subsidiaries 29

List of Figures
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Xenon Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Xenon Pharmaceuticals Inc (XENE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Currence Holding B.V.:企業の戦略・SWOT・財務分析
    Currence Holding B.V. - Strategy, SWOT and Corporate Finance Report Summary Currence Holding B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • AB Electrolux:企業の戦略・SWOT・財務情報
    AB Electrolux - Strategy, SWOT and Corporate Finance Report Summary AB Electrolux - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • JSC Gazprom Neft:企業の戦略・SWOT・財務情報
    JSC Gazprom Neft - Strategy, SWOT and Corporate Finance Report Summary JSC Gazprom Neft - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Wake Forest Innovations-製薬・医療分野:企業M&A・提携分析
    Summary Wake Forest Innovations (Wake Forest), a subsidiary of Wake Forest Baptist Medical Center, is an enterprise that advances the development and commercialization of discoveries; services; and products such as medicines and vaccines, from the Medical Center and Wake Forest University. The compa …
  • Ali Baba:企業の戦略・SWOT・財務情報
    Ali Baba - Strategy, SWOT and Corporate Finance Report Summary Ali Baba - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Avanir Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Avanir Pharmaceuticals Inc (Avanir) a subsidiary of Otsuka America, Inc. is a biopharmaceutical company which focuses on developing medicines for patients suffering from central nervous system disorders. The company’s lead products include NUEDEXTA (AVP-923), a first-in-class dual N-methyl-D …
  • The Andersons Inc (ANDE):企業の財務・戦略的SWOT分析
    The Andersons Inc (ANDE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Inretail Peru Corp. (INRETC1):企業の財務・戦略的SWOT分析
    Inretail Peru Corp. (INRETC1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Summit Midstream Partners LP (SMLP):企業の財務・戦略的SWOT分析
    Summary Summit Midstream Partners LP (SMLP) is an oil and gas company that develops, owns and operates midstream energy infrastructure assets located in unconventional shale resource basins and shale formations across North America. The company operates natural gas, crude oil, and produced water gat …
  • Oilinvest (Netherlands) BV:企業の戦略的SWOT分析
    Oilinvest (Netherlands) BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • CoImmune Inc (ARGS):企業の財務・戦略的SWOT分析
    Summary CoImmune Inc(CoImmune) formerly known as Argos Therapeutics Inc, is a biopharmaceutical company that develops and commercializes immunotherapies for the treatment of infectious diseases and cancer. The company develops a pipeline of products based on its proprietary Arcelis technology platfo …
  • HedgePath Pharmaceuticals Inc (HPPI):製薬・医療:M&Aディール及び事業提携情報
    Summary Hedgepath Pharmaceuticals Inc (Hedgepath), a subsidiary of Mayne Pharma Group Ltd, is a clinical stage biopharmaceutical company that discovers, develops and commercializes novel therapeutics for the treatment of skin, prostrate, and lung cancers. The company is investigating an oral formula …
  • Sanlam Limited:企業の戦略・SWOT・財務情報
    Sanlam Limited - Strategy, SWOT and Corporate Finance Report Summary Sanlam Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Telecom Italia S.p.A.:企業の戦略・SWOT・財務情報
    Telecom Italia S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Telecom Italia S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Taylor Wessing LLP:企業の戦略・SWOT・財務情報
    Taylor Wessing LLP - Strategy, SWOT and Corporate Finance Report Summary Taylor Wessing LLP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Asahi Kasei Corp (3407)-エネルギー分野:企業M&A・提携分析
    Summary Asahi Kasei Corp (Asahi Kasei), formerly Asahi Chemical Industry Co. Ltd., manufactures, processes, and sells chemical products. It is a holding company of Asahi Kasei Group. The product portfolio of the company includes polymers, acrylonitrile, styrene, diagnostic reagents, foam insulation …
  • GrowMax Resources Corp (BOE):企業の財務・戦略的SWOT分析
    Summary GrowMax Resources Corp (GrowMax), formerly Americas Petrogas Inc is an oil and gas company that offers exploration and development of conventional and unconventional oil and gas properties in Argentina. The company explores and develops phosphate and potassium-rich brine resources in northwe …
  • Xylem Inc (XYL)-エネルギー分野:企業M&A・提携分析
    Summary Xylem Inc. (Xylem) is a water technology company that designs, manufactures, and service engineered technologies for water industry. The company’s products portfolio includes testing equipment; filtration, disinfection and biological treatment equipment; controls and systems; and water and w …
  • Comision Federal de Electricidad:企業の戦略的SWOT分析
    Comision Federal de Electricidad - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Achelios Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Achelios Therapeutics Inc (Achelios) is a pharmaceutical company that develops therapeutics for the treatment of pain and inflammation by topically delivered medications. The company’s lead products include Topofen, a product for the indication of acute migraine, prophylactic migraine, osteo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆